[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
November 20, 2013

Patient-Specific Stem Cells and Cardiovascular Drug Discovery

Author Affiliations
  • 1Stanford Cardiovascular Institute
  • 2Department of Medicine, Division of Cardiology
  • 3Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, California

Copyright 2013 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA. 2013;310(19):2039-2040. doi:10.1001/jama.2013.282409

The pharmaceutical industry faces numerous challenges in the development of novel compounds. Phase 2 clinical trial success rates are at a 5-year low of 22%, and the average number of preclinical drug development programs needed to produce a single new drug has increased from 12 to 30 between 2007 and 2012 alone.1 One estimate suggests that the average new drug requires more than $1.8 billion and 12 years from the time of discovery to commercial launch.2 If drug development is to remain commercially viable in the future, the current model for drug discovery and development must undergo a fundamental shift. To reduce these high attrition rates and increased costs, drug developers need to be able to predict and identify potential efficacy and safety issues as early as possible during the drug discovery process. Doing so would enable more attention to be focused on programs with optimal chances of progressing through end-stage clinical trials rather than on costly failures.